247 related articles for article (PubMed ID: 28277880)
21. Advancing precision medicine for prostate cancer through genomics.
Roychowdhury S; Chinnaiyan AM
J Clin Oncol; 2013 May; 31(15):1866-73. PubMed ID: 23589550
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers of response to advanced prostate cancer therapy.
Iacovelli R; Ciccarese C; Schinzari G; Rossi E; Maiorano BA; Astore S; D'Angelo T; Cannella A; Pirozzoli C; Teberino MA; Pierconti F; Martini M; Tortora G
Expert Rev Mol Diagn; 2020 Feb; 20(2):195-205. PubMed ID: 31986925
[No Abstract] [Full Text] [Related]
23. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Robles-Fernandez I; Martinez-Herrera J; Garcia-Rodriguez G; Pascual-Geler M; Cozar JM; Lorente JA
Mol Diagn Ther; 2017 Apr; 21(2):167-178. PubMed ID: 27995550
[TBL] [Abstract][Full Text] [Related]
24. Molecular biomarkers to guide precision medicine in localized prostate cancer.
Smits M; Mehra N; Sedelaar M; Gerritsen W; Schalken JA
Expert Rev Mol Diagn; 2017 Aug; 17(8):791-804. PubMed ID: 28635333
[TBL] [Abstract][Full Text] [Related]
25. Prostate Cancer Biomarkers: Current Status.
Hodges KB; Bachert E; Cheng L
Crit Rev Oncog; 2017; 22(5-6):253-269. PubMed ID: 29604917
[TBL] [Abstract][Full Text] [Related]
26. [Tissue biomarkers in prostate cancer.].
Álvarez Múgica M; Jalón Monzón A
Arch Esp Urol; 2022 Mar; 75(2):185-194. PubMed ID: 35332888
[TBL] [Abstract][Full Text] [Related]
27. Clinically available RNA profiling tests of prostate tumors: utility and comparison.
Na R; Wu Y; Ding Q; Xu J
Asian J Androl; 2016; 18(4):575-9. PubMed ID: 26975490
[TBL] [Abstract][Full Text] [Related]
28. Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer.
Lokeshwar SD; Syed JS; Segal D; Rahman SN; Sprenkle PC
Curr Oncol Rep; 2022 Feb; 24(2):249-256. PubMed ID: 35080739
[TBL] [Abstract][Full Text] [Related]
29. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
30. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
31. Genomics to personalize care of prostate cancer.
Connors LM
J Am Assoc Nurse Pract; 2020 Feb; 32(2):106-108. PubMed ID: 32015276
[TBL] [Abstract][Full Text] [Related]
32. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Kohaar I; Petrovics G; Srivastava S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013716
[TBL] [Abstract][Full Text] [Related]
33. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
Punnen S; Parekh DJ
J Urol; 2017 Aug; 198(2):266-267. PubMed ID: 28629663
[No Abstract] [Full Text] [Related]
34. Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers.
Ahmed ME; Todenhöfer T; Karnes RJ; Seiler R
Eur Urol Focus; 2022 May; 8(3):663-666. PubMed ID: 35843864
[TBL] [Abstract][Full Text] [Related]
35. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.
Alshalalfa M; Schliekelman M; Shin H; Erho N; Davicioni E
Biol Cell; 2015 Jul; 107(7):232-44. PubMed ID: 25900404
[TBL] [Abstract][Full Text] [Related]
36. Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort.
Eure G; Germany R; Given R; Lu R; Shindel AW; Rothney M; Glowacki R; Henderson J; Richardson T; Goldfischer E; Febbo PG; Denes BS
Urology; 2017 Sep; 107():67-75. PubMed ID: 28454985
[TBL] [Abstract][Full Text] [Related]
37. Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX.
Bologna E; Ditonno F; Licari LC; Franco A; Manfredi C; Mossack S; Pandolfo SD; De Nunzio C; Simone G; Leonardo C; Franco G
Clin Pract; 2024 Mar; 14(2):508-520. PubMed ID: 38525718
[TBL] [Abstract][Full Text] [Related]
38. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
39. Whom to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier.
Herlemann A; Washington SL; Eapen RS; Cooperberg MR
Urol Clin North Am; 2017 Nov; 44(4):547-555. PubMed ID: 29107271
[TBL] [Abstract][Full Text] [Related]
40. Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis.
Visser WCH; de Jong H; Melchers WJG; Mulders PFA; Schalken JA
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
